At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
CSJ148 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients
In Brief
A Phase 2 clinical trial evaluating CSJ148 and Placebo for HCMV. Completed, enrolled 86 participants across 17 sites in 6 countries.
Detailed Summary
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHCMV
CountriesBelgium, Germany, Singapore, South Korea, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartJun 2015
Primary CompletionDec 2016
TodayJul 2026
First PostedOct 20, 2014
Enrollment StartJun 2, 2015
Primary CompletionDec 7, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.7 years ago
Interventions
CSJ148biological
CSJ148 IV q 4weeks
Placebodrug
Placebo IV q 4weeks